Yonsei University · Medicine
Professor Minkyu Jung's research lab specializes in translational oncology and immuno-oncology, focusing on identifying novel therapeutic targets and biomarkers in gastrointestinal and lung cancers. The lab investigates tumor microenvironment modulation, particularly through adoptive T cell therapy using chimeric antigen receptor (CAR) T cells, with recent work targeting ICAM-1 in gastric cancer. They also explore predictive and prognostic serum biomarkers such as CEA and CYFRA 21-1 in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors, and examine genetic polymorphisms like SNP-216G/T that influence treatment response. The lab integrates clinical data with molecular and computational approaches to improve personalized cancer therapy.
Figures are computed from collected data and may differ slightly.
Cancer therapy utilizing adoptive transfer of chimeric antigen receptor (CAR) T cells has demonstrated remarkable clinical outcomes in hematologic malignancies. However, CAR T cell application to solid tumors has had limited success, partly due to the lack of tumor-specific antigens and an immune-suppressive tumor microenvironment. From the tumor tissues of gastric cancer patients, we found that intercellular adhesion molecule 1 (ICAM-1) expression is significantly associated with advanced stage
In the Korean NPP cohort, ipilimumab showed similar efficacy and tolerability compared to Western patients, regardless of subtypes. All subtypes should benefit from ipilimumab with consideration of performance status, liver metastasis, and NLR.
The prognostic and predictive value of pre-treatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were assessed in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib or erlotinib. Pre-treatment CEA and CYFRA 21-1 levels were measured in 123 advanced NSCLC patients receiving gefitinib or erlotinib. High CEA levels (h-CEA) were significantly associated with females, patients with adenocarcinoma and non-smokers. Low CYFRA 21-1 lev
In the present study, numerical simulations were conducted to assess rotor aerodynamic performances in hover flight conditions. To calculate the flow around the helicopter rotors in a high-order manner, an unstructured mixed mesh flow solver was developed. The proposed mixed mesh methodology involves body-fitted prismatic/tetrahedral mesh in the near-body region around the blade and adaptive Cartesian mesh in the off-body region. In the off-body region away from the blade, high-order schemes and
SNP-216G/T polymorphism was a potential predictor of clinical outcomes in NSCLC patients treated with EGFR-TKI.
The TS genotype was associated with survival and one DHFR polymorphism was associated with fatigue in NSCLC patients treated with pemetrexed. Further large prospective studies are required to identify other biomarkers that affect patients being treated with pemetrexed for adenocarcinoma of the lung.
h-CEA and l-CYFRA 21-1 may be prognostic and predictive serum markers for higher response and longer survival in patients with advanced NSCLC receiving gefitinib or erlotinib, especially in patients with unknown EGFR mutation status or patients with squamous cell carcinoma.
Through this study, we aimed to validate several biomarkers that have been known to possibly predict the outcomes of the trastuzumab and paclitaxel (TP). Human epidermal growth factor 2 (HER2) positive metastatic breast cancer (MBC) patients who had been treated with TP in single institute from 2006 to 2009 were included in this study. For procured formalin fixed paraffin embedded tumor tissues, HER2 amplification index (AI) and polymorphisms of the immunoglobulin G fragment C receptors (FCGR) w
Open papers in the app to read, cite, and organize with AI.
